European members of WHO Executive Board take hard line on nomination of Novartis official to R&D group

At the 128th meeting of the WHO Executive Board (EB), the European members of the board are reportedly taking a hard line on the proposal by Switzerland to have Paul Herrling, an executive of Novartis, appointed to the WHO Consultative Expert Working Group (CEWG) on R&D financing. Our earlier blogs on this controversy are available here and here).

Continue Reading

Uncategorized

Life Technologies funds seven $1 million medical innovation prizes

On December 14, 2010, Life Technologies Corporation, which among other things owns Ion Torrent, which sells the Ion Personal Genome Machine sequencer, announced seven new medical innovation prizes. The first three prizes are related to improvements in the Ion semiconcudtor sequencing products. Each of the three sequencer prizes is funded at $1 million, and will be awarded to contestants that can achieve the following goals:

  1. produce twice as much sequence data,
  2. Continue Reading

Uncategorized

NIH funded research involving trastuzumab (marketed by Roche under the trade name Herceptin)

13 December 2010

Drugs@FDA
Drug Name(s) HERCEPTIN (Brand Name Drug)
FDA Application No. (BLA) 103792
Active Ingredient(s) TRASTUZUMAB
Company GENENTECH (Roche acquired a majority ownership in 1990, and full ownership in March 2009.)
Original Approval or Tentative Approval Date September 25, 1998

What is Herceptin? How does it work?

Continue Reading

Uncategorized